Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

MetEvoAMR The early metabolic stages in the evolution of antimicrobial resistance

Coordinator
Charite - Universitaetsmedizin Berlin, Germany
Runs
1 March 2023 to 30 June 2026
Status
Running
EU funding
€179k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101069111

What the project is doing

In the project's own words, from its summary on CORDIS.

Antimicrobial resistance (AMR) is a rising global health threat and rapid evolution of resistance against existing or newly developed antibacterial compounds is predicted to lead to 10 million deaths and $60 trillion of lost economic output by 2050. While resistance-conferring mutations, their inheritance and spread by horizontal gene transfer are increasingly well-studied, our understanding of “pre-resistant” cells’ survival and resilience in the presence of lethal antibacterial doses remains unclear.

This proposal is stimulated by recent findings suggesting that the extracellular metabolic environment and metabolic adaptations play an overlooked role in transiently buffering antibiotic lethality and, therefore, increase the emergence of subpopulations of cells and their effective size that supports the evolution of antimicrobial resistance. In this proposal, I will systematically dissect mechanisms at work in subpopulations of “pre-resistant” cells of priority pathogens Pseudomonas aeruginosa and Acinetobacter baumannii that can transiently cope with antimicrobial treatment.

I propose to combine my expertise in bacterial physiology with the Ralser Lab’s ultra-fast, massive-scale proteomics and phenomics technologies. I will systematically investigate the metabolic stress response in clinically relevant conditions, and identify the key metabolic and signalling processes that support the survival of subsets of challenged cells upon exposure to major classes of clinically applied antimicrobials.

Finally, adaptive evolution experiments combined with CRISPR/Cas9 gene editing will validate causal effectors of identified tolerance mechanisms that precede the appearance of resistance-conveying adaptations. Here, I will acquire technical skills in innovative technologies and the host lab will benefit from my experience in working with pathogenic bacteria. I will lead public engagement efforts and disseminate scientific research outputs on an important global health issue.

Topics

Who is involved

OrganisationCityCountryRole
Charite - Universitaetsmedizin BerlinBerlinGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI